| pubmed-article:11350881 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11350881 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11350881 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:11350881 | lifeskim:mentions | umls-concept:C0178630 | lld:lifeskim |
| pubmed-article:11350881 | lifeskim:mentions | umls-concept:C0020402 | lld:lifeskim |
| pubmed-article:11350881 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11350881 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:11350881 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:11350881 | pubmed:dateCreated | 2001-5-14 | lld:pubmed |
| pubmed-article:11350881 | pubmed:abstractText | In vitro low concentrations of hydroxyurea eliminate double-minute chromosomes (dmins) containing amplified drug-resistance genes and oncogenes from cancer cells. This clinical trial investigated whether a noncytotoxic dose of oral hydroxyurea could reduce the number of dmins in cancer cells in patients with advanced ovarian carcinomas. | lld:pubmed |
| pubmed-article:11350881 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350881 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350881 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11350881 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350881 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11350881 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350881 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350881 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350881 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11350881 | pubmed:month | May | lld:pubmed |
| pubmed-article:11350881 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:WeissGG | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:ClarkG MGM | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:Von HoffD DDD | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:McGillJJ | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:KuhnJ GJG | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:DavidsonKK | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:RaymondEE | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:IzbickiMM | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:AllredCC | lld:pubmed |
| pubmed-article:11350881 | pubmed:author | pubmed-author:FaivreSS | lld:pubmed |
| pubmed-article:11350881 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11350881 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:11350881 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11350881 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11350881 | pubmed:pagination | 1171-80 | lld:pubmed |
| pubmed-article:11350881 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:meshHeading | pubmed-meshheading:11350881... | lld:pubmed |
| pubmed-article:11350881 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11350881 | pubmed:articleTitle | Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas. | lld:pubmed |
| pubmed-article:11350881 | pubmed:affiliation | Institute for Drug Development-Cancer Therapy and Research Center, San Antonio, Texas 78245-3217, USA. raymond@igr.fr | lld:pubmed |
| pubmed-article:11350881 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11350881 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11350881 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11350881 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11350881 | lld:pubmed |
